Longeveron (NASDAQ: LGVN; LGVNR), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, will be participating at the American Heart Association Scientific Sessions. The company announced that an abstract outlining long-term survival data from its ELPIS 1 trial of Lomecel-B(TM) for patients with HLHS has been accepted for presentation as a poster at upcoming Scientific Sessions. The sessions are slated to be held Nov. 11–13, 2023, in Philadelphia. The poster is titled “Long-Term Transplant-Free Survival Is Improved in Hypoplastic Left Heart Syndrome with Cell-Based Therapy.” The long-term survival data from the ELPIS 1 trial indicates that children in the trial had 100% survival up to five years of age after receiving Lomecel-B(TM) compared to 20% mortality rate observed from historical control data.
In addition, Longeveron announced that it is partnering with IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its investor communications. According to the announcement, IBN will leverage its investor-based distribution network of 5,000+ key syndication outlets, numerous newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools to strengthen and increase industry awareness for Longeveron. Longeveron’s lead investigational product is Lomecel-B. Data has shown that the product may be effective in dealing with a decrease in immune system function that occurs as humans age as well as a decline in blood vessel functioning, chronic inflammation and other issues. “While there has been a remarkable rise in life expectancy over the last century due to medical and public health advancements, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging,” said IBN director of operations Chris Johnson in the press release. “We’re excited to customize our comprehensive suite of corporate communications solutions for Longeveron as it works to address this unmet medical need through its clinical pipeline, including the expected release of top-line results from its phase 2a CLEAR MIND trial of Lomecel-B for the treatment of Alzheimer’s disease in the coming weeks.”
To view the full press releases, visit https://ibn.fm/23ZS5 and https://ibn.fm/y0l4J
About Longeveron Inc.
Longeveron is a clinical-stage, biotechnology company developing regenerative medicines to address unmet medical needs. The company’s lead investigational product is Lomecel-B(TM), an allogeneic medicinal signaling cell (“MSC”) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action encompassing provascular, proregenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently advancing Lomecel-B through clinical trials in three indications: hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty. To learn more about the company, visit www.Longeveron.com.
NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at http://ibn.fm/LGVN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN